CLINICAL TRIALS PROFILE FOR ESTRADIOL; LEVONORGESTREL
✉ Email this page to a colleague
All Clinical Trials for ESTRADIOL; LEVONORGESTREL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00117273 ↗ | A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens | Completed | Duramed Research | Phase 3 | 2005-06-01 | This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs). Two extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo). |
| NCT00128934 ↗ | Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2005-08-01 | The purpose of this study is to determine whether levonorgestrel (LNG)/ethinyl estradiol (EE) is effective in treating the symptoms of severe premenstrual syndrome (PMS). |
| NCT00161681 ↗ | Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2005-07-01 | The purpose of this study is to determine whether LNG/EE is effective in the treatment of menstrual cycle related symptoms. |
| NCT00195559 ↗ | Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2005-09-01 | The purpose of this study is to determine whether Levonorgestrel/Ethinyl Estradiol (LNG/EE) is effective in treating the symptoms of severe Premenstrual Dysphoric Disorder. |
| NCT00204451 ↗ | Human Ovarian Follicular Dynamics and Emergency Contraception | Completed | Canadian Institutes of Health Research (CIHR) | Phase 4 | 2005-07-01 | The researchers hypothesize that emergency contraception (EC) will initiate the changes associated with atresia or ovulatory failure at all stages of follicular development and that the image attributes associated with atresia will be similar regardless of the diameter of the dominant follicle when ovarian suppression is initiated. Second, changes associated with atresia may be observed, but ovulation of the dominant follicle is unimpeded. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ESTRADIOL; LEVONORGESTREL
Condition Name
Clinical Trial Locations for ESTRADIOL; LEVONORGESTREL
Trials by Country
Clinical Trial Progress for ESTRADIOL; LEVONORGESTREL
Clinical Trial Phase
Clinical Trial Sponsors for ESTRADIOL; LEVONORGESTREL
Sponsor Name
